Skip to main content
SpringerLink
Log in

Dyslipidaemia

Small triumph for fenofibrate therapy in dyslipidaemia

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

The ACCORDION trial, an extension of the ACCORD trial, confirms earlier findings showing that addition of fenofibrate to background statin therapy does not reduce cardiovascular events. However, cardiovascular events are reduced in patients with dyslipidaemia. Future trials with fibrates should restrict inclusion to patients with dyslipidaemia that persists despite statin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561 (2016).

    Article  CAS  Google Scholar 

  2. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).

    Article  CAS  Google Scholar 

  3. Davidson, M. H. et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler. Thromb. Vasc. Biol. 34, 1298–1306 (2014).

    Article  CAS  Google Scholar 

  4. ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).

  5. Elam, M. B. et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. http://dx.doi.org/10.1001/jamacardio.2016.4828 (2017).

  6. Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S. & Gaudet, D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 64, 2525–2540 (2014).

    Article  CAS  Google Scholar 

  7. Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B. & Rademaker, A. W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30, 1945–1951 (2007).

    Article  CAS  Google Scholar 

  8. Staels, B. et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 95, 705–712 (1995).

    Article  CAS  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02104817 (2016).

  10. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT01492361 (2016).

Download references

Author information

Authors and Affiliations

  1. Robert S. Rosenson is at the Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, New York 10029, USA.,

    Robert S. Rosenson

Authors
  1. Robert S. Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Rosenson.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosenson, R. Small triumph for fenofibrate therapy in dyslipidaemia. Nat Rev Cardiol 14, 131–132 (2017). https://doi.org/10.1038/nrcardio.2017.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2017.11

  • Springer Nature Limited

Search

Navigation